Last reviewed · How we verify

Minocycline HCl — Competitive Intelligence Brief

Minocycline HCl (Minocycline HCl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease; Dermatology; Periodontal Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease; Dermatology; Periodontal Disease Small molecule Live · refreshed every 30 min

Target snapshot

Minocycline HCl (Minocycline HCl) — OraPharma. Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Minocycline HCl TARGET Minocycline HCl OraPharma marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin Cefazolin + Gentamicin Mercy Health Ohio marketed Beta-lactam antibiotic + aminoglycoside antibiotic combination Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Neomycin Oral Product Neomycin Oral Product South Australian Health and Medical Research Institute marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
Omadacycline Injection Omadacycline Injection Wake Forest University Health Sciences marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Usual doses of tigecycline Usual doses of tigecycline Air Force Specialized Hospital, Cairo, Egypt marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Doxycycline pre-operatively Doxycycline pre-operatively University of Pittsburgh marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
hand mixed tobramycin hand mixed tobramycin Washington University School of Medicine marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

  1. OraPharma · 2 drugs in this class
  2. Vyne Therapeutics Inc. · 2 drugs in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
  5. Darier · 1 drug in this class
  6. Edward Lain, MD · 1 drug in this class
  7. Generic (originally Pfizer) · 1 drug in this class
  8. Galderma R&D · 1 drug in this class
  9. Johns Hopkins University · 1 drug in this class
  10. Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Minocycline HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/minocycline-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: